The purpose of this study is to assess the effect of bortezomib on myeloma-related bone
disease, analyzing bone mineral density (BMD) in patients with Multiple Myeloma (MMY) who
have received high dose chemotherapy and autologous stem cell transplantation for primary
treatment of MMY (single- or double-transplant). Eligible patients will be randomized (study
treatment assigned by chance like flipping a coin) to either bortezomib or observation alone.
Patients in the bortezomib arm will receive treatment of bortezomib for a total of 4 cycles.
All subjects will be followed for a total of 24 months after randomization.